Desjardins Global Asset Management Inc. Sells 1,293 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Desjardins Global Asset Management Inc. reduced its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 42.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,724 shares of the medical equipment provider’s stock after selling 1,293 shares during the quarter. Desjardins Global Asset Management Inc.’s holdings in Intuitive Surgical were worth $582,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. RB Capital Management LLC grew its stake in shares of Intuitive Surgical by 4.4% in the 1st quarter. RB Capital Management LLC now owns 1,735 shares of the medical equipment provider’s stock valued at $523,000 after buying an additional 73 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Intuitive Surgical by 0.6% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 946,709 shares of the medical equipment provider’s stock valued at $285,603,000 after acquiring an additional 5,233 shares during the period. Baird Financial Group Inc. increased its holdings in shares of Intuitive Surgical by 2.3% during the first quarter. Baird Financial Group Inc. now owns 21,089 shares of the medical equipment provider’s stock valued at $6,362,000 after acquiring an additional 481 shares in the last quarter. Brown Brothers Harriman & Co. raised its position in shares of Intuitive Surgical by 576.7% during the first quarter. Brown Brothers Harriman & Co. now owns 406 shares of the medical equipment provider’s stock worth $122,000 after purchasing an additional 346 shares during the period. Finally, Covestor Ltd lifted its holdings in shares of Intuitive Surgical by 50.4% in the 1st quarter. Covestor Ltd now owns 418 shares of the medical equipment provider’s stock worth $126,000 after purchasing an additional 140 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of Intuitive Surgical stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the transaction, the senior vice president now owns 1,842 shares of the company’s stock, valued at approximately $736,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, VP Fredrik Widman sold 5,041 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $397.07, for a total value of $2,001,629.87. Following the transaction, the vice president now owns 110 shares of the company’s stock, valued at $43,677.70. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Mark Brosius sold 196 shares of Intuitive Surgical stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total value of $78,400.00. Following the sale, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at approximately $736,800. The disclosure for this sale can be found here. In the last quarter, insiders have sold 248,418 shares of company stock valued at $95,927,097. Corporate insiders own 0.90% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on ISRG shares. Citigroup boosted their price target on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada upped their target price on shares of Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a report on Wednesday, January 24th. Barclays lifted their price target on Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a research note on Thursday, January 25th. Mizuho increased their price objective on Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a research note on Thursday, January 25th. Finally, Raymond James raised their target price on Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a report on Thursday, January 25th. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $375.70.

Intuitive Surgical Stock Down 1.2 %

NASDAQ ISRG opened at $374.17 on Thursday. The company’s 50 day moving average is $387.56 and its 200-day moving average is $342.39. The firm has a market cap of $132.62 billion, a P/E ratio of 74.39, a price-to-earnings-growth ratio of 5.88 and a beta of 1.36. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Tuesday, January 23rd. The medical equipment provider reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.48 by $0.12. Intuitive Surgical had a return on equity of 13.11% and a net margin of 25.24%. The firm had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.89 billion. During the same quarter in the prior year, the business posted $0.91 earnings per share. The business’s quarterly revenue was up 16.6% on a year-over-year basis. Equities analysts expect that Intuitive Surgical, Inc. will post 4.93 EPS for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.